Intrinsic PDL1 Signaling Modulates TGFBI-Mediated Growth Suppression in Lung Adenocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Programmed death ligand 1 (PDL1) typically suppresses T-cell immunity via programmed cell death protein 1 (PD1) interaction.
• The intrinsic signaling role of PDL1 in cancer development, independent of immune modulation, is not fully understood.

Purpose of the Study:

• To investigate the role of intrinsic programmed death ligand 1 (PDL1) signaling in lung adenocarcinoma (ADC) oncogenesis.
• To explore the correlation between PDL1 expression levels and patient prognosis in lung ADC.

Main Methods:

• Analysis of PDL1 expression in lung ADC tissues and correlation with patient prognosis.
• Experimental manipulation of PDL1 expression (silencing and overexpression) in lung ADC cell lines.
• Cell cycle analysis, Western blotting for key signaling proteins (FAK, ERK, AKT), and gene expression profiling (TGFBI, CITED2, p21CIP1).
• Pharmacologic and genetic inhibition of FAK.

Main Results:

• Lung adenocarcinomas (ADCs) exhibit deficient PDL1 expression, linked to poorer patient outcomes.
• PDL1 overexpression inhibited lung ADC cell growth and colony formation, while PDL1 silencing promoted proliferation and S-phase entry.
• PDL1 signaling reduced FAK, ERK, and AKT phosphorylation, promoting cell detachment.
• PDL1 regulates TGFBI expression; PDL1 or TGFBI knockdown increased CITED2 and decreased p21CIP1, promoting cell growth.
• FAK inhibition reversed the effects of PDL1/TGFBI knockdown on CITED2 and p21CIP1.

Conclusions:

• Intrinsic PDL1-TGFBI signaling acts as a tumor suppressor in lung ADC by inhibiting FAK activation.
• This pathway influences a molecular switch involving CITED2 and p21CIP1, ultimately leading to cell growth arrest.
• PDL1 expression may serve as a valuable biomarker for predicting lung ADC progression.